New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
To accelerate the development of next-generation radioconjugates to treat cancer
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Both organisations enter into a long- term collaboration to expand patient access in India
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Sen spent a decade with Biocon and held various key roles,
Subscribe To Our Newsletter & Stay Updated
